---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-151979"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:11.056505+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Palvella Therapeutics appoints John Doux, M.D. to Board of Directors

## Summary
- Board increased to 7 members; Dr. Doux appointed as Class III director with term expiring at 2026 Annual Meeting.
- Dr. Doux is a board-certified dermatologist and analyst at Palo Alto Investors LP since 2004.
- Granted option to purchase 6,000 shares vesting in equal monthly installments over 36 months.
- Previously served on Palvella's board before reverse merger (2019-2022).
- Board determined Dr. Doux independent under Nasdaq listing rules.

## SEC filing metadata
- accession: 0001193125-26-151979
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526151979/0001193125-26-151979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526151979/pvla-20260413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-151979
- JSON: https://secwatch.observer/filing/0001193125-26-151979.json
- Plain text: https://secwatch.observer/filing/0001193125-26-151979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.